ALX Oncology Holdings announced that it has entered into a clinical trial collaboration and supply agreement with Sanofi to evaluate evorpacept in combination with SARCLISA (isatuximab-irfc) in patients with multiple myeloma. This collaboration with Sanofi has the potential to advance a new combination therapy for patients with relapsed multiple myeloma who will benefit from novel effective treatment options. Moreover, collaboration expands robust clinical development pipeline with evorpacept, to establish a new and best-in-class foundational immunotherapy in both haematologic and solid tumours. Under the terms of the agreement, Sanofi will conduct a Phase 1/2 study to evaluate the safety, efficacy, pharmacokinetics and biomarker data of evorpacept in combination with SARCLISA and dexamethasone in patients with RRMM. Part 1 will evaluate dosing of evorpacept in combination with standard doses of SARCLISA and dexamethasone to identify a recommended dose. Part 2 will investigate the efficacy and safety of this combination in an expanded population of patients with RRMM. ALX Oncology will supply evorpacept and Sanofi will supply SARCLISA for this study.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!